

Drug Development Considerations for Empiric Antibacterial Therapy in Febrile Neutropenic Patients—FDA Virtual Public Workshop—April 23, 2024

Speakers and Panelists: Affiliations and Disclosures

Radu Botgros, MD

Senior Scientific Officer
Department of Public Health Threats
European Medicines Agency (EMA)
Amsterdam, The Netherlands

Juan Gea-Banacloche, MD

Senior Infectious Diseases Consultant
Division of Clinical Research
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Bethesda, MD

John Farley, MD, MPH

Director
Division of Anti-Infectives (DAI), Office of Infectious Diseases (OID)
Office of New Drugs (OND), CDER, FDA
Silver Spring, MD

Alison Freifeld MD

Professor Emeritus
Department of Medicine
University of Nebraska College of Medicine
Omaha, Nebraska

Kimberly Hanson, MD, MHS

Professor of Medicine and Pathology
Director, Transplant Infectious Diseases, University of Utah
Section Chief, Clinical Microbiology, ARUP Laboratories
Salt Lake City, UT

Douglas Girgenti, MD

Vice President Head of Drug Development
Melinta Therapeutics
Parsippany, NJ

Dmitri Iarikov, MD, PhD

Deputy Division Director
Division of Anti-Infectives (DAI), Office of Infectious Diseases (OID)
OND, CDER, FDA
Silver Spring, MD

Katsuhiko Ichimaru

Review Director
Office of New Drug IV
Pharmaceuticals and Medical Devices Agency (PMDA)
Tokyo, Japan

Rama Kapoor, MD

Senior Medical Officer
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Peter Kim, MD, MS

Division Director
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Gary H. Lyman, MD, MPH (Biostatistics), FASCO, FRCP, FACP

Hutchinson Institute for Cancer Outcomes Research, Cancer Epidemiology, Prevention & Control Program
Division of Public Health Sciences, Fred Hutchinson Cancer Center
Seattle, WA
Adjunct Professor of Medicine, Duke University School of Medicine

Catherine Liu, MD

Professor, Vaccine and Infectious Disease Division
Medical Director, Antimicrobial Stewardship and Outpatient Parenteral Antimicrobial Therapy Programs
Associate Director, Infection Prevention
Fred Hutchinson Cancer Center

Kieren Marr, MD, MBA

Chief Medical Officer
Elion Therapeutics
New York, NY
President, Pearl Diagnostics, Inc.
Baltimore, MD

Robert Pease, MD, MPH

Medical Officer
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Daniel Rubin, PhD

Mathematical Statistician
Division of Biometrics IV, Office of Biostatistics
OTS, CDER, FDA
Silver Spring, MD

Michael Satlin, MD

Clinical Director, Transplantation-Oncology Infectious Diseases Program
Weill Cornell Medical Center
New York, NY

Anita Sheoran, MS, PhD

Biologist
Antimicrobials Branch
Administration for Strategic Preparedness and Response (ASPR)
Biomedical Advanced Research and Development Authority (BARDA)
U.S. Department of Health and Human Services (HHS)
Washington, DC

Adam Sherwat, MD

Deputy Office Director
OID
OND, CDER, FDA
Silver Spring, MD

Lynne Strasfeld, MD

Associate Professor of Medicine, Division of Infectious Diseases
Associate Medical Director, Department of Infection Prevention and Control
Oregon Health and Science University (OHSU)
Portland, OR

Randy Taplitz MD, FIDSA

Professor and Chair, Department of Medicine
City of Hope National Medical Center
Duarte, CA

Andrea J. Zimmer, MD, FACP, FIDSA

Associate Professor of Internal Medicine, Associate Vice Chair of Faculty Development
Medical Director, Oncology Infectious Diseases Program, Fred & Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, NE

Voluntary Disclosures

Dr. Girgenti is Vice President of Drug Development at Melinta Therapeutics, LLC, from which he receives salary and holds equity in the company.

Dr. Hanson received research funding from the NIH and Antibiotic Leadership Group (ARLG), Consultant: Karius and Health Tracks Diagnostics, Advisor: CARB-X, Editor: Journal of Clinical Microbiology and Clinical Infectious Diseases, Honoraria: UptoDate, has also received travel support from the American Board of Internal Medicine (exam committee) and Medscape (speaker).

Dr. Liu has received research support from the NIH and Pfizer. She has received honoraria from the Antibacterial Resistance Leadership Group (ARLG) and consulting fees from the Duke Clinical Research Institute.

Dr. Lyman has served as a consultant for Sandoz, AstraZeneca and Beyond Spring.

Dr. Marr is the Chief Medical Officer for Elion Therapeutics, from which she receives salary and holds equity in the company. She is also President and VP of Clinical Development for Pearl Diagnostics, from which she holds equity and receives licensing revenue as an academic inventor of technology.

Dr Zimmer: received research grant support from AlloVir, Ansun Biopharma, Astellas Pharma Global Development, and Chimerix, Inc. She has received funding from American College of Physicians (ACP) for authoring educational materials as well as travel support or honorariums from ACP, Infectious Diseases Society of America, and National Comprehensive Care Network (NCCN). She is a member of the NCCN guidelines committee for the Prevention and Treatment of Cancer Related Infections as well as the NCCN COVID-19 Vaccine Advisory Committee.